QC
ZNTL icon

Quadrature Capital’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Quadrature Capital’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$78K Sell
33,332
-104,236
-76% -$269K ﹤0.01% 1255
2025
Q4 		$186K Buy
137,568
+76,917
+127% +$112K ﹤0.01% 992
2025
Q3 		$92.2K Buy
60,651
+8,195
+16% +$12.3K ﹤0.01% 885
2025
Q2 		$60.6K Buy
+52,456
New +$69.2K ﹤0.01% 931

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Quadrature Capital's ZNTL Position: Q1 2026 in Review

Quadrature Capital reduced its Zentalis Pharmaceuticals (ZNTL) stake by 76% in Q1 2026, selling an estimated $269K and leaving 33,332 shares worth $78K. The position accounts for ﹤0.01% of the portfolio, ranked #1255.

Quadrature Capital first reported a position in ZNTL in Q2 2025 and has held it in 4 quarters since. The position peaked at $186K in Q4 2025. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Quadrature Capital held 33,332 shares of Zentalis Pharmaceuticals worth $78K as of Q1 2026.
  • Quadrature Capital sold 104,236 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $269K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Quadrature Capital's portfolio in Q1 2026, its #1255 holding.
  • Quadrature Capital first reported a position in Zentalis Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Quadrature Capital's Zentalis Pharmaceuticals position peaked at $186K in Q4 2025.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.